Skip to main content
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
- Weiner, Michael W;
- Veitch, Dallas P;
- Aisen, Paul S;
- Beckett, Laurel A;
- Cairns, Nigel J;
- Green, Robert C;
- Harvey, Danielle;
- Jack, Clifford R;
- Jagust, William;
- Morris, John C;
- Petersen, Ronald C;
- Salazar, Jennifer;
- Saykin, Andrew J;
- Shaw, Leslie M;
- Toga, Arthur W;
- Trojanowski, John Q;
- Initiative, Alzheimer's Disease Neuroimaging
- et al.
Published Web Location
http://www.sciencedirect.com/science/article/pii/S1552526016330722?via=ihubNo data is associated with this publication.
Abstract
Introduction
The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.Methods
ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.Results
Multimodal analyses will provide insight into AD pathophysiology and disease progression.Discussion
ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.